Clinical Trials · NCT05140512
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Luye Pharma Group Ltd.
- Enrollment
- 23
- Start date
- Feb 2021
- Locations
- 1 site, China
- Primary endpoint
- Pharmacokinetic Profile of LY01005 versus ZoLADEX®: Plasma concentration of goserelin over time.